In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research
In a report released yesterday, Randall Stanicky from RBC Capital maintained a Hold rating on Amneal Pharmaceuticals (AMRX), with a price target of $4.00.
In a report released yesterday, Randall Stanicky from RBC Capital maintained a Hold rating on Amneal Pharmaceuticals ( AMRX – Research Report ), with a price target of $4.00 . The company’s shares
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma (URGN). The company's shares closed last Wednesday
In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Urogen Pharma (URGN – Research
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Horizon Therapeutics (HZNP) and Madrigal Pharmaceuticals
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Horizon Therapeutics ( HZNP – Research Report ) and Madrigal Pharmaceuticals ( MDGL – Research Repo
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sientra (SIEN) and Pacira Pharmaceuticals (PCRX) with
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sientra (SIEN
In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Amarin (AMRN). The company's shares closed last Monday at
In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Amarin (AMRN – Research Report).
RBC Capital analyst Randall Stanicky maintained a Buy rating on Perrigo Company (PRGO) on April 8 and set a price target of $58.00. The company's shares

RBC Capital Remains a Hold on AbbVie (ABBV)

02:45am, Monday, 13'th Apr 2020
In a report issued on April 8, Randall Stanicky from RBC Capital maintained a Hold rating on AbbVie (ABBV), with a price target of $79.00. The company's

RBC Capital Remains a Hold on AbbVie (ABBV)

02:45am, Monday, 13'th Apr 2020
In a report issued on April 8, Randall Stanicky from RBC Capital maintained a Hold rating on AbbVie ( ABBV – Research Report ), with a price target of $79.00 . The company’s shares closed last Thu
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE